The REMEDEE Study: A Prospective, Randomized Study to Evaluate the Safety and Efficacy of an Abluminal Sirolimus Coated Bio-engineered Stent (Combo Bio-engineered Sirolimus Eluting Stent)

Trial Profile

The REMEDEE Study: A Prospective, Randomized Study to Evaluate the Safety and Efficacy of an Abluminal Sirolimus Coated Bio-engineered Stent (Combo Bio-engineered Sirolimus Eluting Stent)

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2016

At a glance

  • Drugs Anti-CD34 monoclonal antibody/sirolimus (Primary) ; Paclitaxel
  • Indications Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
  • Focus Therapeutic Use
  • Acronyms REMEDEE Study
  • Sponsors OrbusNeich
  • Most Recent Events

    • 28 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 30 Apr 2015 Planned End Date changed from 1 Jul 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov record.
    • 27 May 2013 Data from this trial have been used to support CE mark approval for COMBO, according to an OrbusNeich media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top